An Open-Label Study to Evaluate the Safety and Tolerability of PCS499 for the treatment of Necrobiosis Lipoidica

Recruiting
99 years or below
All
Phase 2
9 participants needed
1 Location

Brief description of study

The main purpose of this research study is to test the safety and tolerability of PCS499 when given to individuals at a dose of 300 mg, twice a day for 1 week followed by giving PCS499 to individuals at a dose of 900 mg, twice a day, for remaining treatment period. Male or female patients age 18 to 80 years of age, Biopsy-confirmed diagnosis of NL. Procedures include labs, EKG's, Physical exams, questionnaires and a biopsy if not done with-in 5 years and photographs.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 12 Dec 2019. Study ID: 832022

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.